PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
This 2-year study will test the effectiveness of combining parathyroid hormone (PTH) and
alendronate for treating osteoporosis in postmenopausal women. Alendronate is a drug used to
treat osteoporosis and primarily prevents bone loss, whereas PTH increases bone formation. We
will treat the study participants either with PTH and alendronate, alendronate alone, or PTH
alone. We will determine the effects of these treatments by looking for changes in bone
mineral density in the hip and spine.
Phase:
Phase 2
Details
Lead Sponsor:
Dennis Black
Collaborator:
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)